World's Best Scientists 2026 revealed!
Takuji Okusaka

Takuji Okusaka

D-Index & Metrics

Medicine

D-Index
96
Citations
43710
World Ranking
9525
National Ranking
261

Takuji Okusaka publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Takuji Okusaka sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 845 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Takuji Okusaka D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Takuji Okusaka sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 96 D-Index — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Takuji Okusaka is affiliated with the National Cancer Centre in Japan. Their research primarily focuses on oncology within the medical field, with particular attention to pancreatic and hepatic oncology, cholangiocarcinoma and gallbladder cancer, as well as hepatocellular carcinoma treatment and prognosis.

The main fields of study covered in their work include:

  • Medicine

While the subfields of study where their research is concentrated consist of:

  • Oncology
  • Surgery
  • Pulmonary and Respiratory Medicine
  • Hepatology
  • Epidemiology

The core topics addressed in Takuji Okusaka's publications are:

  • Pancreatic and Hepatic Oncology Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Gallbladder and Bile Duct Disorders
  • Pediatric Hepatobiliary Diseases and Treatments
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer Genomics and Diagnostics
  • Neuroendocrine Tumor Research Advances

Frequent collaborators include:

  • Masafumi Ikeda
  • Chigusa Morizane
  • Susumu Hijioka
  • Yoshikuni Nagashio
  • Junji Furuse

Okusaka has published extensively in various scientific venues, with a strong presence in the following journals:

  • Journal of Clinical Oncology
  • Endoscopy
  • Annals of Oncology
  • Japanese Journal of Clinical Oncology
  • Journal of Gastroenterology

Some of the recent papers contributing to the field include:

  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma (2020, Journal of Clinical Oncology)
  • Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (2022, NEJM Evidence)
  • Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study (2021, Journal of Clinical Oncology)
  • A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. (2022, Journal of Clinical Oncology)
  • Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition (2020, Journal of Hepato-Biliary-Pancreatic Sciences)

Best Publications

  • Everolimus for Advanced Pancreatic Neuroendocrine Tumors

    James C. Yao;Manisha H. Shah;Tetsuhide Ito;Catherine Lombard Bohas

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn

  • Genomic spectra of biliary tract cancer

    Hiromi Nakamura;Yasuhito Arai;Yasushi Totoki;Tomoki Shirota

  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

    Richard S. Finn;Masafumi Ikeda;Andrew X. Zhu;Max W. Sung

  • Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial

    Andrew X. Zhu;Joon Oh Park;Baek Yeol Ryoo;Chia Jui Yen

  • Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

    Akihiro Fujimoto;Yasushi Totoki;Tetsuo Abe;Keith A. Boroevich

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.

    Y Matsumura;T Hamaguchi;T Ura;K Muro

  • Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

    T Okusaka;K Nakachi;A Fukutomi;N Mizuno

  • Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

    Yasushi Totoki;Kenji Tatsuno;Kyle R. Covington;Hiroki Ueda

  • Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

    Hideki Ueno;Tatsuya Ioka;Masafumi Ikeda;Shinichi Ohkawa

  • Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer

    Akihiro Fujimoto;Mayuko Furuta;Yasushi Totoki;Tatsuhiko Tsunoda

  • Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

    Masatoshi Kudo;Kazuho Imanaka;Nobuyuki Chida;Kohei Nakachi

  • JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

    Masatoshi Kudo;Osamu Matsui;Namiki Izumi;Hiroko Iijima

  • Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

    Masatoshi Kudo;Kazuomi Ueshima;Masafumi Ikeda;Takuji Torimura

  • Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

    Yasuhito Arai;Yasushi Totoki;Fumie Hosoda;Tomoki Shirota

  • Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

    Hedy L Kindler;Tatsuya Ioka;Dirk J Richel;Jaafar Bennouna

  • Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis

    Tetsuhide Ito;Hisato Igarashi;Kazuhiko Nakamura;Hironobu Sasano

  • Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials

    Juan W Valle;J Furuse;M Jitlal;S Beare

Frequent Co-Authors

Junji Furuse
Junji Furuse Kyorin University
Masatoshi Kudo
Masatoshi Kudo Kindai University
Tomoo Kosuge
Tomoo Kosuge National Cancer Center
Andrew X. Zhu
Andrew X. Zhu Harvard University
Narikazu Boku
Narikazu Boku St. Marianna University School of Medicine
Shoji Nakamori
Shoji Nakamori Osaka University
Hiromitsu Kumada
Hiromitsu Kumada Fukuoka University
Shuichi Kaneko
Shuichi Kaneko Kanazawa University
Ian Chau
Ian Chau Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a future in Medicine but want flexible learning options, a range of related online degrees can help you start or advance your healthcare career. With rising demand for qualified healthcare professionals, taking courses online has become more accessible and respected by employers.

For those interested in entry-level nursing, online nursing programs offer affordable and flexible paths to get started as a registered nurse. If you are already a registered nurse seeking career advancement, rn to bsn online programs help you earn a bachelor’s degree, which can open doors to leadership and specialized roles.

Those from a non-nursing background can consider online direct entry msn options, fast-tracking your path to a master’s in nursing. For experienced nurses looking to move into research, teaching, or executive roles, a phd in nursing delivers advanced knowledge and skills.

Each of these online pathways helps build a strong foundation in healthcare, offering options to match different interests, education levels, and career goals within the medical field.

Best Scientists Citing Takuji Okusaka

Trending Scientists

Recently Published Articles